Trial · NCT01576354
Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis
NCT01576354, Phase 2, Unknown, University of Zurich
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis. Trials, record NCT01576354. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01576354
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis
- NCT number
- NCT01576354
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- University of Zurich
- Conditions
- Multiple Sclerosis
- Interventions
- Prolonged-release Fampridine, Placebo
- First posted
- 2012-04-12
- Last updated
- 2015-12-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changed walking pattern on treadmill under fampridine treatment. | Assessment during double-blind fampridine and double-blind placebo treatment (each for 6 weeks, assessments in week 4 and 6). Averaged values from the 2 different testing sessions per treatment period will be compared. | Electromyographic, kinematic and kinetic gait parameters describing stability, balance, posture, foot placement, loading, intra- and interlimb coordination and general dynamics of lower extremities will be recorded during treadmill walking. |
| Secondary | 6 minute Walking Test | The test will be performed at all Visits (14) over a period of 18 weeks. Subjects will complete the task once per testing session/visit. | |
| Secondary | Timed 25-foot Walk test | The test will be performed 13 times over a period of 18 weeks. Subjects will complete the task four times per testing session/visit, two times with and two times without walking aids (in case walking aids are required). | |
| Secondary | Timed-Up-and-Go test | Subjects will complete the task two times per testing session/visit, once with and once without walking aids (in case walking aids are required). The task will be performed 4 times over a period of 18 weeks. | |
| Secondary | Berg Balance Scale | The subjects' performances are rated 4 times over a period of 18 weeks. | |
| Secondary | Dynamic Gait Index | The performance is rated 4 times over a period of 18 weeks. | |
| Secondary | LEMMT | Lower Extremity Manual Muscle Test will be performed 4 times over a period of 18 weeks. | modified British Medical Research Council (BMRC) manual muscle test: hip flexors, knee flexors, knee extensors, and ankle dorsiflexors |
| Secondary | Actimeter | The device will be worn for 14 days during each double-blind treatment periods (two 6-weeks-periods). | |
| Secondary | 12-item MS Walking Scale | Subjects are asked to complete the standardized questionnaire 4 times over a period of 18 weeks. | |
| Secondary | Fatigue Questionnaire (WEIMuS) | Subjects are asked to complete the standardized questionnaire at each visit except the Screening Visit (i.e., 13 times) over a period of 18 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01576354
GET https://conductscience.org/api/trials/v1/NCT01576354/registered